INOCARDIA LIMITED’s Post

Pathalys pharma secures $105 million series B financing. Oversubscribed financing paves path to NDA submission and pre-commercialization efforts for upacicalcet.  Upacicalcet is a novel calcimimetic that can be delivered intravenously at the end of the hemodialysis session via pre-filled syringe and has been demonstrated to effectively reduce levels of parathyroid hormone(PTH) and may have a better tolerability profile for patients. Upacicalcet can be used in secondary hyperparathyroidism (SHPT) to address an unmet need in the management of advanced chronic kidney disease (CKD). Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gsg24G8S Keywords: Upacicalcet; CaSR; secondary hyperparathyroidism (SHPT); building blocks  

J&J, Legend solidify Carvykti's lead in earlier multiple myeloma with strong survival showing After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti has once again mounted a major benefit—this time in prolonging patients’ lives. A single dose of the star BCMA CAR-T therapy significantly slashed the risk of death by 45% compared with two traditional combination treatments in myeloma patients who had received at least one prior line of therapy, according to an update of the phase 3 CARTITUDE-4 trial. Combinations of either Bristol Myers Squibb’s Pomalyst, Takeda’s Velcade and dexamethasone (PVd), or J&J’s Darzalex, Pomalyst and dexamethasone (DPd) served as the trial's comparators. #pharmaceuticalresearch #drugdiscovery #biotechnology #pharma #healthcar #medicine #science #research #innovation #health

PolTREG S.A. - Precision Medicine Online a leading pharmaceutical magazine, presented PolTREG to its U.S. readers in a broad-ranging interview with CEO Prof Piotr Trzonkowski. PolTREG’s investigational Treg therapies “could halt progression, or possibly even cure some patients with type 1 diabetes”, is how the magazine put it.

💊 Clopidogrel ranks as one of the most prescribed antiplatelet medications in North America. (1) However, just 15% of the drug is metabolized by CYP450 enzymes into its active form. (1) Among these enzymes, CYP2C19 stands out with the most significant role in both stages of bioactivation. (1) Thus, clinical outcomes of patients treated with clopidogrel is impacted by CYP2C19 genotype (1). Discover how Genomadix can aid in CYP2C19 genotype-guided antiplatelet therapy for personalized treatment at www.genomadix.com  🧬 #Pharmacogenetics #PrecisionMedicine #PersonalizedMedicine #stroke #PCI   1.Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. doi:10.1002/cpt.2526

#EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the #esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview, EoE affects more than 450,000 people in the United States and has been identified by the American #Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual. Today, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage #biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). - Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks - The fourth cohort showed the greatest percentage change in histology (EoEHSS2) scores of any cohort to date - The RESOLVE Phase 1b/2a trial is progressing as anticipated with no serious adverse events reported in all four fully-dosed cohorts "The RESOLVE trial is progressing rapidly and we continue to observe positive data on efficacy and safety outcomes with EP-104GI, with the fifth cohort expected to read out in November 2024," said Dr. James Helliwell, Chief Executive Officer of Eupraxia. "Overall, we are encouraged by the data that we have seen across a number of key metrics and remain optimistic that we'll see further improvements in patient response as the trial progresses towards an optimal dosing level." https://lnkd.in/gVGEm_Dd

🌟 Drug Spotlight: Humira - A life-saving $200 billion medication 🌟 Disease: Rheumatoid Arthritis and other chronic inflammatory diseases Company: AbbVie 2020 U.S. Sales: $20.39 billion Key Patent Expiration: 2023 Before Humira, chronic inflammatory diseases were often debilitating with limited treatment options. This revolutionary drug changed the game, turning despair into hope for millions. Impact: Humira has been a lifeline for countless patients. Discovery Story: Developed by AbbVie, Humira was the first fully human monoclonal antibody approved by the FDA in 2002, treating conditions from arthritis to Crohn's disease. With its patent expiration in 2023, biosimilars have already entered the market. Amgen’s Amjevita, which was approved in 2016, entered the market at the end of January of 2023. This should now make this essential treatment more accessible and affordable. #HealthcareInnovation #Pharma #RheumatoidArthritis #DrugDiscovery #Humira #Patents

Precision Medicine Online, a leading pharmaceutical magazine, presented PolTREG to its U.S. readers in a broad-ranging interview with CEO Prof Piotr Trzonkowski. PolTREG’s investigational Treg therapies “could halt progression, or possibly even cure some patients with type 1 diabetes”, is how the magazine put it. Much of the interview focused on PolTREG’s Phase 2 clinical trial in presymptomatic diabetes patients, children for whom PolTREG hopes its treatment with its cellular therapy may mean they stay in clinical remission for the rest of their lives. But reporter Jessica Kim Cohen also talked about PolTREG’s future plans to develop therapies for auto-immune diseases like multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and amyotrophic lateral sclerosis. For a look at the story, click here (subscription required): https://lnkd.in/dZp5sBvm #T1D #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes #multiplesclerosis

Drug formulation is one of the cornerstones of a successful drug, even more so for the modern medicines, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. In this article for the Drug Target Review, co-founder and CEO of Vasodynamics Ningfeng Fiona Li, shares how their approach integrating formulation development in the drug development pathway is vital for the development of new therapies and improved outcome for the disease control and overall wellbeing of cancer patients.   Find the full article ‘The art and science of drug formulation’ here:  https://lnkd.in/eGU9MGjz

🌟 Excited to Share My Latest Publication! 🌟 I'm thrilled to announce that my review article titled "Review on Influence of Proton Pump Inhibitors on Gut Microbiota" has been published in the International Journal of Pharmaceutical Sciences. This work delves into the impact of proton pump inhibitors (PPIs) on gut microbiota, highlighting: - Microbiota changes: Reduced microbial richness and shifts in bacterial taxa, such as an increase in potentially pathogenic bacteria like Enterococcus and Streptococcus. - Clinical implications: Dysbiosis linked to conditions like Clostridium difficile infection, small intestinal bacterial overgrowth (SIBO), and inflammatory bowel disease (IBD). While PPIs remain essential for managing acid-related disorders, understanding their broader effects on gut health is critical for optimizing patient care. I would like to extend my heartfelt gratitude to my guides, Dr. Satish S and Dr. A R Shabaraya, for their invaluable support, encouragement, and insights throughout the research process. #GutHealth #ClinicalPharmacy #MicrobiotaResearch #PharmaceuticalSciences #PPIs #Gratitude